Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia.
C. R. Mehta
Consultant or Advisory Role - Sunesis Pharmaceuticals
G. Michelson
Employment or Leadership Position - Sunesis Pharmaceuticals
Stock Ownership - Sunesis Pharmaceuticals
M. Salganik
Consultant or Advisory Role - Sunesis Pharmaceuticals
J. Feaster
Consultant or Advisory Role - Sunesis Pharmaceuticals
R. Allen
Employment or Leadership Position - Sunesis Pharmaceuticals
Stock Ownership - Sunesis Pharmaceuticals
A. L. Cahill
Consultant or Advisory Role - Sunesis Pharmaceuticals
J. A. Fox
Employment or Leadership Position - Sunesis Pharmaceuticals
Stock Ownership - Sunesis Pharmaceuticals
S. B. Ketchum
Employment or Leadership Position - Sunesis Pharmaceuticals
Stock Ownership - Sunesis Pharmaceuticals
F. Ravandi
Consultant or Advisory Role - Sunesis Pharmaceuticals
Honoraria - Sunesis Pharmaceuticals
Research Funding - Sunesis Pharmaceuticals
H. P. Erba
Consultant or Advisory Role - Sunesis Pharmaceuticals
Research Funding - Sunesis Pharmaceuticals
G. J. Schiller
Consultant or Advisory Role - Sunesis Pharmaceuticals
Research Funding - Sunesis Pharmaceuticals
R. K. Stuart
Consultant or Advisory Role - Sunesis Pharmaceuticals
Research Funding - Sunesis Pharmaceuticals
Expert Testimony - Sunesis Pharmaceuticals
N. Vey
Honoraria - Sunesis Pharmaceuticals
E. J. Feldman
Consultant or Advisory Role - Sunesis Pharmaceuticals